NEW YORK, February 28, 2017 /PRNewswire/ --
The Biotech industry is today's focus on Stock-Callers.com, and linedup for assessment are the following equities: ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), and Marinus Pharmaceuticals Inc. (NASDAQ: MRNS). These companies belong to the
On Monday, shares in Boston, Massachusetts headquartered ZIOPHARM Oncology Inc. recorded a trading volume of 1.44 million shares. The stock ended the day at $6.39, climbing 4.75% from the last trading session. The Company's shares have advanced 16.61% in the last one month and 19.44% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 5.43% and 7.58%, respectively. Furthermore, shares of ZIOPHARM Oncology, which focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology, have a Relative Strength Index (RSI) of 51.63.
On February 16th, 2017, ZIOPHARM announced that net loss applicable to common shareholders for Q4 2016 was $14.8 million, or $(0.11) per share, compared to a net loss of $9.5 million, or $(0.07) per share, for Q4 2015. The Company ended Q4 2016 with cash and cash equivalents of approximately $81.1 million, which the Company believes will be sufficient to fund its currently planned activities into Q4 2017. See our free and comprehensive research report on ZIOP at:
Victoria, Canada headquartered Aurinia Pharmaceuticals Inc.'s stock saw a slight drop of 0.54%, finishing yesterday's session at $3.70 with a total trading volume of 1.05 million shares. The Company's shares have gained 21.31% in the last month, 18.21% over the previous three months, and 76.19% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 30.47% and 27.63%, respectively. Additionally, shares of Aurinia Pharma, which engages in the development of a therapeutic drug to treat autoimmune diseases in Canada, have an RSI of 64.53.
On February 14th, 2017, Aurinia Pharmaceuticals announced the results of a supportive Phase-I safety, pharmacokinetic (PK) and pharmacodynamic (PD) study in healthy Japanese patients which supports further development of voclosporin in this patient population. The Company stated that based on evaluations comparing the Japanese ethno-bridging data vs. previous PK and PD studies in non-Japanese patients, voclosporin demonstrated no statistically significant differences in exposure with respect to Area Under the Curve measurements. Furthermore, the PK parameters in Japanese patients were generally consistent with previously evaluated PK parameters in non-Japanese volunteers. AUPH free research report PDF is just a click away at:
Shares in San Diego, California-based Arena Pharmaceuticals Inc. ended the session 6.80% higher at $1.57. The stock recorded a trading volume of 2.02 million shares, which was above its three months average volume of 1.61 million shares. The Company's shares have gained 9.03% in the last one month and 10.56% on an YTD basis. The stock is trading 6.80% above its 50-day moving average. Moreover, shares of Arena Pharma, which focuses on developing novel small molecule drugs for various therapeutic areas, have an RSI of 57.98.
On February 14th, 2017, Arena Pharma announced the appointment of three new members to its Board of Directors. Jayson Dallas, M.D., Oliver Fetzer, Ph.D., and Garry A. Neil, M.D. have joined as independent directors. The new directors are all international business executives with significant drug development and commercial expertise. In addition, the Company announced that the current directors Harry F. Hixson, Jr., Ph.D. and Donald D. Belcher will be retiring from the Board at the annual meeting. Sign up for your complimentary report on ARNA at:
At the closing bell on Monday, Radnor, Pennsylvania-based Marinus Pharmaceuticals Inc.'s stock dropped 0.73%, finishing at $1.36. A total volume of 203,112 shares was traded. The Company's shares have gained 6.75% in the last month, 17.24% over the previous three months, and 34.65% on an YTD basis. The stock is trading 18.60% above its 50-day moving average. Additionally, shares of Marinus Pharma, which focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders, have an RSI of 58.97.
On February 14th, 2017, Marinus Pharma announced the publication of preclinical data in the January issue of Neuropharmacology, showing that its positive allosteric modulator of GABAA, ganaxolone ameliorates many of the behavioral abnormalities in a mouse model of adult Angelman syndrome (AS). Evidence from experimental models suggests that AS may be associated with deficient extrasynaptic GABAA receptor function. Register for free on Stock-Callers.com and download the latest research report on MRNS at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Cyanosis is the bluish or purplish discoloration of the skin and mucus membranes due to lack of ...
Find out about travel shots or vaccination before you travel to your destination country. Travel ...
Hay fever is caused by allergy to pollen and is characterized by runny or blocked nose, sneezing, ...View All